Scope
The EAU sexual and reproductive health guideline spans male hypogonadism, erectile and ejaculatory disorders, penile disease, priapism and male infertility. This selected clinical summary emphasizes diagnostic confirmation, fertility preservation, cardiovascular and treatment safety, urgent ischaemic priapism, and coordinated assessment of both partners.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Confirm symptomatic hypogonadism and protect fertility
- Diagnose late-onset hypogonadism from compatible symptoms plus consistently low testosterone, not a screening questionnaire or isolated result. Measure fasting morning total testosterone between 07:00 and 10:00; if below 12 nmol/L, repeat on at least two separate occasions before treatment. Evaluate interfering medicines and comorbidities. [1]
- Use LH and FSH to distinguish primary from secondary hypogonadism; assess SHBG and calculated free testosterone when indicated. With secondary hypogonadism, check prolactin when low desire or suggestive symptoms occur, and obtain pituitary MRI for raised prolactin, mass symptoms or other anterior-pituitary deficits. [1]
- Address organic causes, obesity, relevant medicines and comorbidities before testosterone treatment. Do not prescribe testosterone to eugonadal men or to treat infertility, and do not give it to men wishing to father children because it suppresses spermatogenesis. [1]
- Check contraindications and cardiovascular risk before testosterone therapy. Active breast/prostate cancer, current fertility intentions, haematocrit at least 54% and uncontrolled heart failure are major exclusions; severe LUTS and borderline-high haematocrit require additional assessment. Previously treated prostate cancer needs a separate specialist eligibility discussion. [1]
- Monitor testosterone and haematocrit at three, six and twelve months, then yearly. A haematocrit above 54% requires dose adjustment or withdrawal, with venesection when necessary; only restart at a lower dose after normalization and consider a topical formulation. Higher-risk patients need closer monitoring. [1]
Assess erectile dysfunction as a medical and sexual-health problem
- Take a full medical, sexual and psychosocial history, use a validated erectile-function questionnaire and perform focused examination. Check glucose, lipids and total testosterone to identify reversible contributors, rather than immediately proceeding to invasive testing. [1]
- Assess cardiovascular suitability for sexual activity. Unstable angina, uncontrolled hypertension, severe heart failure or dangerous arrhythmias require cardiac assessment; indeterminate-risk patients need further exercise testing before resuming sexual activity. [1]
- Start lifestyle/risk-factor treatment alongside ED care and use a PDE5 inhibitor as first-line drug therapy. Never combine it with organic nitrates, nitric-oxide donors including recreational poppers, or nicorandil. Check correct use and patient understanding before declaring treatment failure. [1]
- Offer cognitive behavioural therapy, including the partner when indicated, together with medical treatment. Discuss vacuum devices, topical/intraurethral alprostadil or intracavernosal injections according to preferences, suitability and informed counselling; injections may be an alternative first-line or second-line option. [1]
- A penile prosthesis is an option when other ED treatments fail or after informed patient preference. Low-intensity shockwave treatment has a weaker recommendation for selected vasculogenic ED; do not present it as a universally effective replacement for established treatment. [1]
Distinguish ejaculatory disorders and their causes
- Diagnose premature ejaculation through history of latency, perceived control, distress and interpersonal effects, plus examination. Do not order routine laboratory or physiological tests unless findings direct them. Treat coexisting ED, other sexual dysfunction or genitourinary infection first. [1]
- For lifelong premature ejaculation, dapoxetine or lidocaine/prilocaine spray are first-line options. Daily SSRIs or daily/on-demand clomipramine are off-label second-line alternatives; on-demand tramadol is an off-label third-line option requiring caution. [1]
- For low sexual desire, assess medical and sexual history, physical findings and endocrine causes; review medicines that may contribute. Testosterone is indicated only when desire problems accompany signs and symptoms of testosterone deficiency. [1]
Use disease stage and realistic goals in penile disorders
- For Peyronie disease, document duration, erection pain, deformity, intercourse difficulty and ED, and objectively assess curvature and length. NSAIDs can treat acute-phase pain; shockwave therapy may help pain but should not be used to correct curvature. [1]
- Consider Peyronie surgery only when disease is stable and deformity compromises intercourse. Evaluate length, curvature, erectile function and expectations before choosing the operation. Evidence for intralesional platelet-rich plasma remains limited and should be explained. [1]
- When penile size is the concern, examine and measure appropriately, screen for dysmorphic concerns and refer suspected body dysmorphic disorder for mental-health counselling. Do not use testosterone to enlarge the penis after puberty or inject silicone, paraffin or petroleum jelly for girth enhancement. [1]
Treat ischaemic priapism as an emergency
- Distinguish ischaemic from non-ischaemic priapism with history, examination and corporal blood-gas analysis in the emergency setting. Start ischaemic treatment as early as possible, within four to six hours; investigate causes without postponing penile treatment. [1]
- For ischaemic priapism, begin corporal aspiration/washout and use an intracavernosal sympathomimetic if it persists. For priapism caused by vasoactive intracavernosal injections, a sympathomimetic replaces aspiration as the first step. Repeat appropriate medical measures before surgical escalation. [1]
- For ischaemic priapism, phenylephrine is the preferred adrenergic agent, requiring blood-pressure and pulse monitoring during treatment and every 15 minutes for one hour after injection. Intracavernosal sympathomimetics are contraindicated in malignant or poorly controlled hypertension and must not be combined with monoamine-oxidase inhibitors. [1]
- Sickle-cell-associated ischaemic priapism needs the same urgent penile management as idiopathic disease; do not use exchange transfusion as the primary treatment or delay local treatment for supportive measures. Proceed to surgery after aspiration and drug treatment fail. [1]
- After confirming non-ischaemic priapism, immediate emergency treatment is generally unnecessary. Begin with site-specific perineal compression and use selective arterial embolization when conservative treatment fails. Recurrent ischaemic episodes still require the acute ischaemic pathway. [1]
Investigate infertility in both partners and tailor intervention
- Evaluate infertility after twelve months of regular unprotected intercourse without conception, and assess both partners together. In the male partner, take reproductive, family and lifestyle history, examine and obtain semen analysis; female age and ovarian reserve affect timing and treatment choices. [1]
- Use WHO-standard semen analysis and repeat at least two consecutive analyses if the baseline result is abnormal. In oligozoospermia or azoospermia, evaluate total testosterone, FSH and LH. Confirm non-obstructive azoospermia with two centrifuged semen samples lacking sperm. [1]
- Offer karyotyping and genetic counselling for azoospermia or sperm concentration below 5 million/mL. Perform Y-chromosome microdeletion testing at concentrations at or below 1 million/mL and consider it below 5 million/mL. Discuss inheritance to sons before ICSI when a Y deletion is present. [1]
- Do not attempt testicular sperm retrieval with complete AZFa or AZFb deletions. For other azoospermia, distinguish obstruction from impaired production; reconstruction or retrieval/ICSI depends on the cause, partner’s ovarian reserve and the couple’s preferences, with genetic counselling where abnormalities exist. [1]
- Treat a clinical varicocele in an infertile man with abnormal semen and otherwise unexplained couple infertility when the female partner has good ovarian reserve. Do not treat a subclinical varicocele or infertility-associated varicocele with normal semen solely to improve fertility. [1]
- Support weight, exercise, smoking and alcohol changes. Do not routinely offer antioxidants, probiotics/prebiotics, SERMs or aromatase inhibitors for idiopathic infertility. Men with hypogonadotropic hypogonadism seeking fertility may need gonadotropin treatment; testosterone replacement is not fertility treatment. [1]
Limitations and use
- This is a selected cross-topic summary from the formal recommendations and relevant safety discussions, not every procedure, fertility protocol, genetic indication or medication regimen. Priapism injection doses, preparation and surgical techniques require the complete emergency protocol. Detailed Peyronie therapies, penile reconstruction, cancer-survivor testosterone eligibility, assisted reproduction and paediatric care are outside the summary. Local drug approval and off-label status require confirmation.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Sexual and reproductive health
Selected recommendation material consulted
Publication details
- Issuing organisation
- EAU
- Resource type
- Clinical guideline · House clinical summary
- Source setting
- Europe
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.